NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50242-0260-01 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | June 29, 2020 | In Use | |
50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
51144-0003-01 | 51144-0003 | Tisotumab vedotin | TIVDAK | 40.0 mg/4mL | Immunotherapy | Drug Antibody Conjugate | Tissue factor | Intravenous | Sept. 20, 2021 | In Use | |
57277-0107-45 | 57277-0107 | carboplatin Injection | Carboplatin | 450.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 29, 2016 | In Use | |
57665-0331-01 | 57665-0331 | Cytarabine | DepoCyt | 50.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal | Oct. 22, 2010 | June 30, 2018 | No Longer Used |
57884-3021-00 | 57884-3021 | Docetaxel | Docetaxel | 40.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 15, 2017 | Oct. 29, 2021 | In Use |
58181-3043-05 | 58181-3043 | Lomustine | Gleostine | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Nov. 5, 2015 | June 30, 2018 | No Longer Used |
59148-0047-91 | 59148-0047 | Busulfan | Busulfex | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Feb. 13, 2015 | Jan. 31, 2021 | No Longer Used |
59148-0070-91 | 59148-0070 | Busulfan | Busulfex | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Feb. 4, 1999 | In Use | |
59676-0960-01 | 59676-0960 | Doxorubicin Hydrochloride | Doxil | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Nov. 17, 1995 | Sept. 30, 2020 | No Longer Used |
59676-0960-02 | 59676-0960 | Doxorubicin Hydrochloride | Doxil | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Nov. 17, 1995 | June 30, 2020 | No Longer Used |
59676-0966-01 | 59676-0966 | doxorubicin hydrochloride | Doxorubicin Hydrochloride liposome | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | June 26, 2017 | Sept. 30, 2020 | No Longer Used |
59676-0966-02 | 59676-0966 | doxorubicin hydrochloride | Doxorubicin Hydrochloride liposome | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | June 26, 2017 | Oct. 31, 2020 | No Longer Used |
60429-0925-90 | 60429-0925 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec. 30, 2016 | Dec. 31, 2020 | No Longer Used |
60505-6113-06 | 60505-6113 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6114-00 | 60505-6114 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6115-02 | 60505-6115 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
61126-0003-10 | 61126-0003 | Cisplatin | Platinol | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | Jan. 13, 2012 | In Use |
61126-0004-01 | 61126-0004 | Cisplatin | Platinol-AQ | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | In Use | |
61126-0004-02 | 61126-0004 | Cisplatin | Platinol-AQ | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | Jan. 13, 2012 | In Use |
61703-0303-46 | 61703-0303 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 31, 1990 | In Use | |
61703-0341-06 | 61703-0341 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | April 9, 2007 | Oct. 31, 2017 | No Longer Used |
61703-0341-09 | 61703-0341 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | April 2, 2007 | May 31, 2019 | No Longer Used |
61703-0344-18 | 61703-0344 | Fludarabine Phosphate | Fludarabine Phosphate | 50.0 mg/2mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Sept. 25, 2008 | Sept. 30, 2021 | No Longer Used |
62756-0826-40 | 62756-0826 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 20, 2012 | In Use | |
62756-0827-40 | 62756-0827 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 20, 2012 | In Use | |
62856-0001-10 | 62856-0001 | Altretamine | Hexalen | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Triazines | Oral | Dec. 26, 1990 | Dec. 31, 2019 | No Longer Used |
62856-0600-01 | 62856-0600 | Decitabine | Dacogen | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 3, 1996 | Dec. 31, 2018 | No Longer Used |
63304-0158-01 | 63304-0158 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
63304-0158-30 | 63304-0158 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
63304-0962-01 | 63304-0962 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
63304-0962-30 | 63304-0962 | Bromocriptine Mesylate | Bromocriptine Mesylate | 2.5 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec. 22, 2016 | In Use | |
63323-0121-02 | 63323-0121 | Methotrexate Sodium | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | April 3, 2003 | Nov. 23, 2015 | In Use |
63323-0637-10 | 63323-0637 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Aug. 31, 2018 | In Use | |
63459-0600-10 | 63459-0600 | Arsenic Trioxide | Trisenox | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Oct. 15, 2000 | Aug. 15, 2021 | No Longer Used |
63539-0197-90 | 63539-0197 | Dacomitinib | Vizimpro | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb. 1, 2019 | In Use | |
63739-0932-11 | 63739-0932 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 1, 2015 | March 31, 2017 | In Use |
63739-0971-17 | 63739-0971 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 1, 2015 | March 31, 2017 | In Use |
63759-0003-01 | 63759-0003 | azacitidine for | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Dec. 5, 2016 | In Use | |
63759-3000-01 | 63759-3000 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 31, 2016 | In Use | |
63759-3001-01 | 63759-3001 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 31, 2016 | In Use | |
64370-0532-01 | 64370-0532 | Vinorelbine tartrate | Navelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Nov. 15, 2005 | Oct. 31, 2021 | No Longer Used |
64370-0532-02 | 64370-0532 | Vinorelbine tartrate | Navelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Nov. 15, 2005 | Oct. 31, 2021 | No Longer Used |
64842-1020-01 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 7, 2015 | In Use | |
64842-1020-02 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov. 11, 2015 | In Use | |
64842-1020-03 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 21, 2015 | In Use | |
64842-1025-01 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 7, 2015 | In Use | |
64842-1025-02 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov. 11, 2015 | In Use | |
64842-1025-03 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct. 21, 2015 | In Use | |
66215-0016-60 | 66215-0016 | Mechlorethamine Hydrochloride | Valchlor | 0.012 g/60g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Topical | Oct. 21, 2013 | May 31, 2020 | No Longer Used |
Found 10,000 results in 2 milliseconds — Export these results